MENU
[Partnership and collaboration models]
Grey Stone Memorial Hospital is a private medical facility which has an idea for a vaccine to a deadly disease, but does not have the capacity to make the vaccine itself. It is considering partnering with a well-known pharmaceutical company in order to bring the vaccine to market. What is the biggest risk to Grey Stone?
Suggested Answer: A
Get Premium L4M6 Questions
as Interactive Web-Based Practice Test or PDF
Real Exam Format
Detailed Explanations
Instant Access
Get Your Practice Test
35 comments · newest first
TR
Trina
11 months ago
Wait, uninformed stakeholders could really derail this?
VI
Viola
11 months ago
I think increased costs are a bigger concern.
SH
Shelia
11 months ago
Totally agree with the IP rights risk!
LE
Lenita
11 months ago
Low quality product? That’s a real possibility!
NA
Nakisha
11 months ago
Intellectual property rights can be a huge risk in partnerships.
TO
Tonja
12 months ago
Uninformed stakeholders could definitely pose a problem, but I think the intellectual property rights issue might overshadow that in this scenario.
CA
Catarina
12 months ago
I feel like the quality of the product is crucial, but I don't know if that's the biggest risk. We talked about quality control in similar practice questions.
BU
Bulah
1 year ago
I'm not entirely sure, but I think increased costs could be a risk too. If the pharmaceutical company raises prices, it might affect Grey Stone's budget.
TE
Tegan
1 year ago
I remember discussing how intellectual property rights can be a major concern in partnerships, especially when sharing proprietary information.
AN
Anabel
1 year ago
Low quality product is an interesting option. If the hospital doesn't have full control over the manufacturing process, there's a risk the vaccine could end up being subpar. I'll have to weigh that against the other choices.
DA
Darci
1 year ago
Increased costs seems like the most likely answer here. Partnering with a big pharma company is going to come with a lot of overhead and fees that could really eat into the hospital's profits.
LA
Lashon
1 year ago
Hmm, I'm not sure about this one. There are a few potential risks to consider. I think I need to think through the different partnership models and how they could impact the hospital's position.
JO
Jolene
1 year ago
This seems like a pretty straightforward question. The biggest risk is probably intellectual property rights - the hospital might lose control of the vaccine formula if they partner with the pharmaceutical company.
CH
Cherelle
1 year ago
I agree, the IP rights are crucial. They better get a good lawyer to draw up that contract!
CL
Clarence
1 year ago
A) Intellectual Property Rights
LE
Lenny
1 year ago
D) Uninformed stakeholders
BO
Boris
1 year ago
C) Low quality product
MA
Maile
1 year ago
B) Increased Costs
SU
Sue
1 year ago
A) Intellectual Property Rights
ME
Merri
1 year ago
D) Uninformed stakeholders
BE
Bernardine
1 year ago
C) Low quality product
QU
Queenie
1 year ago
B) Increased Costs
LA
Lang
1 year ago
A) Intellectual Property Rights
IS
Isadora
1 year ago
Uninformed stakeholders? That's a good one. How about 'Disgruntled shareholders who can't get their hands on the vaccine first'?
GI
Gilberto
1 year ago
Low quality product is a risk too. They need to ensure the pharma company can manufacture the vaccine to their standards.
FR
Francene
1 year ago
B) Increased Costs
RE
Rebecka
1 year ago
A) Intellectual Property Rights
AL
Alverta
1 year ago
But what about B) Increased Costs? Partnering with a big company could lead to unexpected expenses for Grey Stone.
QU
Quiana
1 year ago
I agree with Eric. If they partner with a pharmaceutical company, they might lose control over their vaccine's intellectual property.
ER
Eric
1 year ago
I think the biggest risk to Grey Stone is A) Intellectual Property Rights.
AR
Arlette
1 year ago
Increased Costs could also be a major concern. The partnership might end up costing more than Grey Stone expected.
WI
Willis
1 year ago
I think the biggest risk to Grey Stone is Intellectual Property Rights. They need to make sure their vaccine formula is protected before partnering with the pharma company.
VE
Veronika
1 year ago
C) Low quality product
EL
Elke
1 year ago
B) Increased Costs
FR
Freeman
1 year ago
A) Intellectual Property Rights